Mr Prentki succeeds Gregory Turnbull, who will remain a company director, a member of the board’s executive committee and, until a permanent successor is recruited, interim CFO.
Mr Prentki joins AP Pharma from Easton Healthcare Ventures, a business development and consulting company he founded in 2005. Previously, he served for seven years as president and on the board of directors at Progenics Pharmaceuticals.
Mr Prentki earned his MBA at the University of Detroit, and holds an undergraduate degree in microbiology and public health from Michigan State University.
Paul Goddard, chairman of AP pharma, said: “We believe that Ron will provide the strong leadership we need as we further develop a pipeline of products based upon our bioerodible drug delivery system and in particular, our lead product APF530, for the prevention of nausea and vomiting in chemotherapy patients.”